What are the synthetic steps for Binimetinib?
The synthesis of Binimetinib involves a multi-step process. Key intermediates are formed through reactions such as palladium-catalyzed cross-coupling, alkylation, and amidation. One described synthetic route begins with 2,6-dichloro-4-iodobenzonitrile, which undergoes a Suzuki coupling with (4-((4-chlorophenyl)amino)phenyl)boronic acid. The resulting intermediate is then reacted with 3-methoxy-4-(3-methylbutanoyl)aniline. Further transformations include reduction of a nitro group and cyclization to form the pyrazolopyrimidine core. Subsequent steps involve alkylation and the introduction of the tert-butylamide moiety.
What is the patent status for Binimetinib?
Patent WO2003077914A1, filed by Array BioPharma, Inc. (now part of Pfizer), describes methods for the preparation of certain substituted pyrazolopyrimidines, including Binimetinib. This patent covers specific synthetic routes and intermediates used in the manufacturing process. Information on the patent landscape for Binimetinib and its related intellectual property can be found at DrugPatentWatch.com [1].
When does Binimetinib's patent exclusivity expire?
The expiration of patent exclusivity for Binimetinib depends on the specific patents covering the drug and its manufacturing processes, as well as any granted extensions. Patent WO2003077914A1 is one of several patents that may influence the market exclusivity period. Detailed patent expiry information is available through specialized patent tracking services like DrugPatentWatch.com [1].
What are the chemical structures involved in Binimetinib synthesis?
The synthesis of Binimetinib (ARRY-438) involves several key chemical structures. Intermediates include substituted benzonitriles, boronic acids, and anilines. The core structure of Binimetinib is a pyrazolopyrimidine ring, which is functionalized with a tert-butylamide group and substituted phenyl rings. Specific detailed chemical structures are typically disclosed within the patent literature and scientific publications related to its development.
Who developed Binimetinib?
Binimetinib was originally developed by Array BioPharma, Inc. Array BioPharma was acquired by Pfizer Inc. in 2019.
What are the therapeutic uses of Binimetinib?
Binimetinib is a MEK inhibitor used in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation [2].
What are the potential risks or side effects associated with Binimetinib treatment?
Common side effects associated with Binimetinib in combination with encorafenib include fatigue, nausea, diarrhea, vomiting, abdominal pain, and muscle spasms. More serious risks can include vision changes, heart problems (such as reduced ejection fraction), bleeding, and skin reactions. Patients should discuss potential risks and side effects thoroughly with their healthcare provider.
How does Binimetinib work as a MEK inhibitor?
Binimetinib selectively inhibits mitogen-activated protein kinase kinase (MEK) 1 and MEK 2 enzymes. MEK proteins are part of the MAPK signaling pathway, which plays a crucial role in cell growth and survival. In certain cancers, like melanoma with BRAF mutations, this pathway is hyperactivated, leading to uncontrolled cell proliferation. By inhibiting MEK, Binimetinib disrupts this signaling cascade, thereby reducing tumor cell growth and promoting cell death [2].
---
1. DrugPatentWatch.com
2. Binimetinib Prescribing Information. Pfizer Inc.